EXC 001 drug, co-developed by Excaliard and Isis Pharmaceuticals, is an antisense oligonucleotide that will hinder the process of fibrosis.
As per the deal, Pfizer will provide Excaliard an upfront payment and contingent payments.
EXC 001 has demonstrated data in Phase 2 study in reducing scar severity.
Pfizer plans to continue development of EXC 001 to treat patient groups suffering from skin scarring, once the acquisition is complete.
The transaction is expected to complete by the end of this year.